Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy (INHERIT)

Henning Bundgaard

Status and phase: Completed; Phase 2

Conditions: Hypertrophic Cardiomyopathy

Treatments: Drug: Placebo; Drug: Losartan

Study type: Interventional

Funder types: Other

Identifiers

NCT01447654

2011-001191-19

Details and patient eligibility

About

Objective The objective of the study is to assess the structural and functional cardiac effects of treatment with losartan in patients with hypertrophic cardiomyopathy (HCM).

Design The study is a randomized, placebo-controlled, double-blinded trial. The follow-up period is 12 months. 130 patients with HCM will be included in predefined subgroups. Genotype positive relatives with borderline hypertrophy (> 13 mm) will also be included. Data on individuals with borderline hypertrophy will be analysed separately from the rest of the cohort.

Primary outcome Ventricular hypertrophy assessed as left ventricular mass and maximal wall thickness.

Enrollment: 130 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertrophic cardiomyopathy
• > 18 years
• Sinus rhythm

Exclusion criteria

• EF < 50 %
• Treatment with RAS-inhibitor
• Contraindications to losartan

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

130 participants in 2 patient groups, including a placebo group

Losartan

Active Comparator group

Treatment:

Drug: Losartan

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo